EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

E Livingstone, H Gogas, L Kandolf-Sekulovic, F Meier, T K Eigentler, M Ziemer, P A M Terheyden, A H Gesierich, R A Herbst, K C Kähler, D C Ziogas, Z Mijuskovic und 12 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.112941 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von E Livingstone und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: University Hospital Essen, F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansVemurafenibProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsMutationAzetidinesPiperidinesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Checkpoint inhibitionFirst-lineMelanomaRun-inSequenceTargeted therapy

Substanzen

VemurafenibProto-Oncogene Proteins B-rafcobimetinibAzetidinesPiperidinesatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
  • Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Ger…
  • Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Centre for Dermatooncology,…
  • Department of Dermatology, University of Leipzig Medical Center, Leipzig, Germany.

Förderung

  • University Hospital Essen
  • F. Hoffmann-La Roche

Zitieren

APA

Livingstone, E., Gogas, H., Kandolf-Sekulovic, L., Meier, F., Eigentler, T. K., Ziemer, M., Terheyden, P. A. M., Gesierich, A. H., Herbst, R. A., Kähler, K. C., Ziogas, D. C., Mijuskovic, Z., Garzarolli, M., Garbe, C., Roesch, A., Ugurel, S., Gutzmer, R., Grob, J. J., Kiecker, F., …, & Schadendorf, D. (2023). Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.112941

Vancouver

Livingstone E, Gogas H, Kandolf-Sekulovic L, Meier F, Eigentler TK, Ziemer M, et al. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.112941

BibTeX
@article{Livingstone2023,
  author = {Livingstone, E and Gogas, H and Kandolf-Sekulovic, L and Meier, F and Eigentler, T K and Ziemer, M and Terheyden, P A M and Gesierich, A H and Herbst, R A and Kähler, K C and Ziogas, D C and Mijuskovic, Z and Garzarolli, M and Garbe, C and Roesch, A and Ugurel, S and Gutzmer, R and Grob, J J and Kiecker, F and Utikal, J and Windemuth-Kieselbach, C and Eckhardt, S and Zimmer, L and Schadendorf, D},
  title = {Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.112941}
}
Kostenlos starten →